Clinical trial · no report yet · Phase 3
NCT03474107
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
- NCT03474107 ↗
- Completed
- Astellas Pharma Global Development, Inc.
- 105 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 44 | |
| YouTube | 32 | |
| X threads | 27 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Ureteral Cancer; Urothelial Cancer; Bladder Cancer
- Interventions
- Enfortumab Vedotin; Docetaxel; Vinflunine; Paclitaxel
- Arms
- Arm A: Enfortumab Vedotin 1.25 mg/kg · Experimental
- Arm B: Chemotherapy · Active comparator
- Cross-over Extension (COE) · Experimental
- Enrollment
- 608
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Astellas Pharma Global Development, Inc. with Seagen Inc.
- Start
- Jun 27, 2018
- Primary completion
- Jul 15, 2020
- Results posted
- Yes
- Registry record
- NCT03474107 · updated Jan 9, 2026
Publications
linked from the registry- Rosenberg JE, Mamtani R, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Sridhar SS, Pappot H, Gurney H, Bedke J, van der Heijden MS, Galli L, Keam B, Masumori N, Meran J, O'Donnell PH, Park SH, Grande E, Sengelov L, Uemura H, Skaltsa K, Campbell M, Matsangou M, Wu C, Hepp Z, McKay C, Powles T, Petrylak DP. Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy. Eur Urol. 2024 Jun;85(6):574-585. doi: 10.1016/j.eururo.2024.01.007. Epub 2024 Feb 28. PubMed 38418343
- Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12. PubMed 33577729